PRISM BioLab focuses on developing technology for proprietary, small molecule, drug discovery for undruggable targets: PepMetics® - transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable in the field of oncology, cirrhosis, gastrointestinal disorders... The company established a Library designed to mimic α-helix or β-turn peptides using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Several programs are under investigation amongst which: PRI724 (targeting CBP/beta-catenin) – licensed to Ohara Pharmaceuticals in the field of cirrhosis, E7386 ( targeting CBP/beta-catenin) – licensed to Eisai in the field of oncology, and internal pipelines in the field of oncology.
Perseus Proteomics developed an antibody drug discovery platform based on phage display. It focuses on therapeutic antibody development targeting transferrin receptor (TfR) for various blood cancer diseases. The company licensed out 2 product candidates and possesses 1 internal product candidate (PPMX-T003) for development in Polycythemia Vera (excess prodution of red blood cells), a precursor to other hematological malignancies. in Japan. PPMX-T003 targets TfR that is expressed on the cell membrane and regulates cellular iron uptake in all cells, especially those manufaturing hemoglobin. The cellular iron uptake is essential for these cell survival and proliferation. The trial in polycythemia investigates the feasibility of reducing red blood cells to a normal level, avoiding the need for nedessary blood letting to avoid complications, such as uncontrolled hypertension and thrombotic episodes.
DeuterOncology is developing DO-2 or DO 2’s active metabolite DO 5: novel MET and RAS pathway inhibitors in the family of Epidermal Growth Factor Receptor (EGFR) inhibitors. Its initial focus is on the treatment of the exon-14 skipping mutant subset (3-4%) of Non-small Cell Lung Cancer (NSCLC) patients. Ultimately it is the company’s ambition to become the partner of choice for EGFR inhibitors in a range of indications including NSCLC, colorectal and pancreatic cancer.
J-Pharma develops novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with selective agents. J-Pharma’s intellectual property embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. The company focusses on drug development targeting the L-type Amino Acid Transporter 1 (LAT 1) for Cancer and Autoimmune diseases. Products are JPH203 for the treatment of patients with Advanced, Refractory Biliary Tract Cancer, and OKY-034 for the treatment of patients with Advanced, Refractory Pancreatic Cancer. Another program is evaluating JPH203 and OKY-034 for the treatment of patients with autoimmune diseases.
Epics Therapeutics is developing first-in-class drugs in oncology based on RNA epigenetics. The company focuses on discovery and development of small molecule inhibitors of RNA-modifying enzymes.
Epics Therapeutics has also acquired assets from the ex-Ogeda GPCR discovery platform. The most advanced program is EP282 (GPR43/FFAR2): an oral small molecule for the treatment of gastrointestinal inflammatory disorders and cancer.